Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

NCT: NCT05027984 · ACTIVE_NOT_RECRUITING

NCT IDNCT05027984
StatusACTIVE_NOT_RECRUITING
Start Date2021-06-30
Completion2030-03-31
SponsorCentro per la Lotta Contro l'Infarto - Fondazione Onlus (OTHER)
First posted
Last updated

Brief Summary

The INTERCLIMA (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome) is a multi-center, prospective, randomized trial of optical coherence tomography (OCT)-based versus physiology-based (i.e. fractional flow reserve\[FFR\]/instantaneous Wave-Free Ratio\[iFR\]/resting full-cycle ratio\[RFR\]) treatment of intermediate (40-70% diameter stenosis), non-culprit coronary lesions in acute coronary syndrome (ACS) patients undergoing coronary angiography. About 1420 patients with ACS will be randomized into the study at approximately 40 sites worldwide.

Frequently Asked Questions

What is Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS?

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS is a clinical trial registered under NCT05027984. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05027984?

The current status of NCT05027984 (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS) is: ACTIVE_NOT_RECRUITING.

When did Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS start?

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS started on 2021-06-30.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.